NSCLC: Empfehlung für Gefitinib

Christina Berndt

Tóm tắt

Từ khóa


Tài liệu tham khảo

Inoue A et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24(1):54–9.